{
    "2020-05-10": [
        [
            {
                "time": "",
                "original_text": "全球新冠疫苗若研发成功对药用玻璃需求测算【太平洋医药】",
                "features": {
                    "keywords": [
                        "新冠疫苗",
                        "研发成功",
                        "药用玻璃",
                        "需求测算",
                        "太平洋医药"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药",
                        "制药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "复星集团总裁助理陈波：优秀品牌是企业的牵引机和助推器",
                "features": {
                    "keywords": [
                        "复星集团",
                        "总裁助理",
                        "陈波",
                        "优秀品牌",
                        "企业",
                        "牵引机",
                        "助推器"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "企业品牌"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "复星医药(02196-HK)子公司新药临床试验注册审评获药监局受理",
                "features": {
                    "keywords": [
                        "复星医药",
                        "子公司",
                        "新药",
                        "临床试验",
                        "药监局",
                        "受理"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药",
                        "制药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "复星医药(02196-HK)子公司新药获台卫生福利部同意用于晚期实体瘤治疗临床试验",
                "features": {
                    "keywords": [
                        "复星医药",
                        "子公司",
                        "新药",
                        "台湾",
                        "卫生福利部",
                        "晚期实体瘤",
                        "临床试验"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药",
                        "制药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}